• Anja Wollny, Attila Altiner, Anne Daubmann, Eva Drewelow, Christian Helbig, Susanne Löscher, Michael Pentzek, Sara Santos, Karl Wegscheider, Stefan Wilm, and Christin Löffler.
• Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057, Rostock, Germany.
• Bmc Fam Pract. 2019 Jun 25; 20 (1): 8787.

BackgroundDoes an intervention designed to foster patient-centered communication and shared decision making among GPs and their patients with poorly controlled type 2 diabetes mellitus reduce the level of HbA1c.MethodsThe DEBATE trial is a cluster-randomized controlled trial conducted in German primary care and including patients with type 2 diabetes mellitus having an HbA1c level of 8.0% (64 mmol/mol) or above at the time of recruitment. Data was measured before intervention (baseline, T0), 6-8 months (T1), 12-14 months (T2), 18-20 months (T3), and 24-26 months (T4) after baseline. Main outcome measure is the level of HbA1c.ResultsIn both, the intervention and the control group the decline of the HbA1c level from T0 to T4 was statistically significant (- 0.67% (95% CI: - 0.80,-0.54%; p < 0.0001) and - 0.64% (95% CI: - 0.78, - 0.51%; p < 0.0001), respectively). However, there was no statistically significant difference between both groups.ConclusionsAlthough the DEBATE trial was not able to confirm effectiveness of the intervention tested compared to care as usual, the results suggest that patients with poorly controlled type 2 diabetes are able to improve their blood glucose levels. This finding may encourage physicians to stay on task to regularly approach this cohort of patients.Trial RegistrationThe trial was registered at ISRCTN registry under the reference ISRCTN70713571 .

28 keywords...

hide…